Aligos Therapeutics, Inc. (NASDAQ:ALGS) Receives Average Recommendation of “Moderate Buy” from Analysts

Aligos Therapeutics, Inc. (NASDAQ:ALGS) has earned a consensus rating of “Moderate Buy” from the seven brokerages that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, five have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $38.50.

ALGS has been the topic of a number of recent analyst reports. Cantor Fitzgerald restated an “overweight” rating on shares of Aligos Therapeutics in a research note on Friday, May 29th. Weiss Ratings upgraded shares of Aligos Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, July 10th. Lake Street Capital initiated coverage on Aligos Therapeutics in a report on Thursday, May 28th. They issued a “buy” rating and a $45.00 target price on the stock. Finally, Wall Street Zen upgraded Aligos Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Sunday, May 17th.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in ALGS. Rockefeller Capital Management L.P. increased its holdings in Aligos Therapeutics by 900.0% during the 4th quarter. Rockefeller Capital Management L.P. now owns 10,000 shares of the company’s stock worth $93,000 after purchasing an additional 9,000 shares during the period. Susquehanna International Group LLP bought a new position in shares of Aligos Therapeutics during the 3rd quarter worth $99,000. HRT Financial LP purchased a new position in shares of Aligos Therapeutics during the fourth quarter valued at $106,000. DRW Securities LLC purchased a new position in shares of Aligos Therapeutics during the fourth quarter valued at $111,000. Finally, XTX Topco Ltd bought a new stake in shares of Aligos Therapeutics in the second quarter valued at about $100,000. Hedge funds and other institutional investors own 60.43% of the company’s stock.

Aligos Therapeutics Trading Up 4.2%

Shares of ALGS opened at $4.25 on Wednesday. The firm has a fifty day simple moving average of $5.48 and a two-hundred day simple moving average of $6.64. The firm has a market cap of $26.31 million, a PE ratio of -0.49 and a beta of 2.26. Aligos Therapeutics has a 1-year low of $3.98 and a 1-year high of $13.69.

Aligos Therapeutics (NASDAQ:ALGS) last released its quarterly earnings results on Thursday, May 7th. The company reported ($2.21) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.29) by $0.08. Aligos Therapeutics had a negative return on equity of 139.47% and a negative net margin of 1,919.68%.The firm had revenue of $2.83 million for the quarter, compared to the consensus estimate of $0.25 million. As a group, research analysts forecast that Aligos Therapeutics will post -7.47 EPS for the current fiscal year.

About Aligos Therapeutics

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.